As required under Regulations 30 and 33, we are attaching herewith the our Quarterly Results as on Dec-2025. Kindly take the same on records. Directors
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Colinz Laboratories Ltd (BSE: 531210) submitted its unaudited financial results for the quarter and nine months ended 31 December 2025, along with an unqualified Limited Review Report from statutory auditor Vora & Associates. Revenue from operations for Q3 FY26 stood at Rs. 143.41 lakhs, marginally down from Rs. 146.65 lakhs in Q3 FY25, while nine-month revenue fell to Rs. 438.82 lakhs from Rs. 507.63 lakhs — a decline of about 13.5% YoY. Profit after tax for Q3 FY26 jumped to Rs. 8.36 lakhs (up ~57% from Rs. 5.33 lakhs) helped by lower employee costs and absence of deferred tax impact, though nine-month PAT was largely flat at Rs. 34.33 lakhs versus Rs. 34.62 lakhs. EPS for Q3 came in at Rs. 0.33 vs Rs. 0.21, and for nine months at Rs. 1.36 vs Rs. 1.37. The company operates only in pharmaceutical formulations and reported no exceptional items or segment changes.
Mixed picture for shareholders — the sharp Q3 PAT recovery is a positive signal on profitability, but the sustained double-digit revenue decline over nine months remains a concern. With no new growth drivers, exceptional items, or guidance disclosed, the stock is likely to see only a muted reaction absent broader pharma sector cues.